ALL PODCASTS

  • 25 November 2020 Speaker: Assoc Prof Dr David Sim SC-SG-00592 SGLT2 inhibitors and Heart Failure: What's New?
    Our host speaks with Assoc Prof Dr David Sim, Consultant Cardiologist and President of the Heart Failure Society Singapore (HFSS) and the Director of the Heart Failure Programme at National Heart Centre Singapore, to discuss the clinical findings from the EMPEROR-Reduced trial, the role of SGLT2 inhibitors in heart failure treatment and the updates to the recently published Heart Failure Guidelines by the HFSS.
    Note: Empagliflozin is not indicated for the treatment of heart failure with reduced ejection fraction.

    References:

    1. Packer, M et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. NEJM 2020; 383:1413-1424 (Source)
    2. Heart Failure Society Singapore – 2020 CPG on the Diagnosis and Management of Heart Failure – A Comprehensive Updated Guideline. (Source)
  • 22 July 2020 Speaker: Dr Aslannif Roslan SC-SG-00515 EMPA-HEART study: Mechanistic Insight of Empagliflozin Mediated Cardiac Benefits
    Our host speaks with Dr Aslannif, Cardiologist at National Heart Institute Malaysia and the former chairperson of Society of Cardiac Imaging Malaysia (SCIM) to discuss on the clinical findings from EMPA-HEART CardioLink-6 study.

    References:

    1. Verma S. et al. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. Circulation August 2019; 140 (21): 1693–1702
    2. Luca N. et al. Regression of left ventricular mass in hypertensive patients treated with perindopril/indapamide as a first-line combination: The REASON echocardiography study. American Journal of Hypertension. August 2004; 17 (8): 660-667
    3. Abdi-Ali A et al. LV Mass Independently Predicts Mortality and Need for Future Revascularization in Patients Undergoing Diagnostic Coronary Angiography. JACC Cardiovasc Imaging March 2018;11 (3) :423-433
  • 15 June 2020 Speaker: Dr Gerard Leong, Dr Saiful Bahari Kassim SC-SG-00498 Why Metabolic Syndrome Matters in Diabetes and Heart Failure
    Our host speaks with Dr Saiful Bahari Kassim, Consultant Endocrinologist from Gleneagles Hospital KL and Dr Gerard Leong, Specialist in Cardiology practising at Gerard Leong Cardiology Clinic, Thomson Medical Centre Singapore, to discuss about why metabolic syndrome matters in diabetes and heart failure. They also discuss about the management of diabetic patients with heart failure in the context of metabolic syndrome.
  • 21 May 2020 Speaker: Dr Doreen Tan, Dr Ng Tat Ming, Dr Wang Aiwen SC-SG-00355 | PC-SG-100534 Who SAID we can't ACE prescribing in the setting of COVID-19? – Part I
    Our host speaks with 3 pharmacists representing the Pharmaceutical Society of Singapore – Dr Doreen Tan, Dr Ng Tat Ming and Dr Wang Aiwen – to discuss the use of medications in the setting of COVID-19. In Part I, they discuss the use of NSAIDs, aspirin and ACE inhibitors/ARBs during the coronavirus pandemic, as well as the risk of patients with hypertension and diabetes in the context of COVID-19.

    References:

    1. Fang L, et al. Lancet 2020. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? (Source)
    2. Pharmaceutical Society of Singapore. COVID-19 Advice for the General Public. (Source)
    3. WHO. Coronavirus disease (COVID-19) advice for the public: Myth-busters. (Source)
    4. ESC Guidance for the Diagnosis and Management of CV disease during the COVID-19 Pandemic. April 2020. (Source)
    5. Singapore Cardiac Society, Heart Failure Society (Singapore) and Academy of Medicine Singapore – Chapter of Cardiology Joint Position Statement on COVID-19 and use of ARB/ACEi. (Source)
  • 21 May 2020 Speaker: Dr Doreen Tan, Dr Ng Tat Ming, Dr Wang Aiwen SC-SG-00356 | PC-SG-100535 Who SAID we can't ACE prescribing in the setting of COVID-19? – Part II
    Our host speaks with 3 pharmacists representing the Pharmaceutical Society of Singapore – Dr Doreen Tan, Dr Ng Tat Ming and Dr Wang Aiwen – to discuss the use of medications in the setting of COVID-19. In Part II, they discuss some medications being investigated as treatment for COVID-19, e.g. remdesivir, hydroxychloroquine, lopinavir-ritonavir, favipiravir, etc. and some considerations to take into account when using these agents in COVID-19.

    References:

    1. FDA. Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment. (Source)
    2. Sanders JM, et al. JAMA 2020. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. (Source)
    3. Guidicessi JR, et al. Mayo Clin Proc 2020. Guidance for navigating QTc prolonging and torsadogenic potential of possible pharmacotherapies for COVID-19. (Source)
    4. MOH Singapore Telemedicine Guidelines 2015, updated 2018. (Source)
  • 21 May 2020 Speaker: Dr Doreen Tan, Dr Ng Tat Ming, Dr Wang Aiwen SC-SG-00357 | PC-SG-100536 Who SAID we can't ACE prescribing in the setting of COVID-19? – Part III
    Our host speaks with 3 pharmacists representing the Pharmaceutical Society of Singapore – Dr Doreen Tan, Dr Ng Tat Ming and Dr Wang Aiwen – to discuss the use of medications in the setting of COVID-19. In Part III, they discuss the risk of thromboembolism and the use of anticoagulants during the COVID-19 pandemic and our guests share their most important takeaways when prescribing in the setting of COVID-19.

    References:

    1. Sanders JM, et al. JAMA 2020. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. (Source)
    2. ESC Guidance for the Diagnosis and Management of CV disease during the COVID-19 Pandemic. April 2020. (Source)
    3. Steffel J, et al. Eur Heart J 2018;39(16):1330-1393. 2018 EHRA Practical Guide on the use of NOACs in patients with AF. (Source)
    4. WHO. Coronavirus disease (COVID-19) advice for the public: Myth-busters. (Source)
    5. Guidicessi JR, et al. Mayo Clin Proc 2020. Guidance for navigating QTc prolonging and torsadogenic potential of possible pharmacotherapies for COVID-19. (Source)